BACKGROUND: A systematic review and meta-analysis was performed to compare the outcomes of oral appliances (OAs) with those of CPAP in treatment of patients with obstructive sleep apnea (OSA). METHODS: Relevant studies were retrieved from the following electronic databases, up to and including September 2012: MEDLINE, PubMed, EMBASE, and Central Register of Controlled Trials. The main outcomes were Epworth Sleepiness Scale score, health-related quality of life, cognitive performance, blood pressure, apnea-hypopnea index (AHI), arousal index, minimum S pO 2 , percent rapid eye movement sleep, treatment usage, side effects, treatment preference, and withdrawals. RESULTS: Fourteen trials were finally included in this review. Our results demonstrated that the effects on Epworth Sleepiness Scale score (P ‫؍‬ .31 and .09 in crossover and parallel-group trials), health-related quality of life, cognitive performance, and blood pressure of OAs and CPAP were similar. Besides, pooled estimates of crossover trials suggested a significant difference in favor of CPAP regarding AHI (P < .001), arousal index (P ‫؍‬ .001), and minimum S pO 2 (P < .001), while pooled estimates of parallel-group trials showed a significant difference in favor of CPAP regarding AHI (P < .001) and percent rapid eye movement sleep (P ‫؍‬ .02). Moreover, OAs and CPAP yielded fairly similar results in terms of treatment usage (P ‫؍‬ .26 for hours/night in crossover trials, and P ‫؍‬ .14 for hours/night and P ‫؍‬ .19 for nights/week in parallel-group trials), treatment preference, side effects, and withdrawals (P ‫؍‬ .34 in parallel-group trials). CONCLUSIONS: CPAP yielded better polysomnography outcomes, especially in reducing AHI, than OAs, indicating that OAs were less effective than CPAP in improving sleep-disordered breathing. However, similar results from OAs and CPAP in terms of clinical and other related outcomes were found, suggesting that it would appear proper to offer OAs to patients who are unable or unwilling to persist with CPAP.
Introduction
Obstructive sleep apnea (OSA) is characterized by recurrent obstruction of the upper airway, often resulting in oxygen desaturation and arousal from sleep. 1 Excessive daytime sleepiness, snoring, reduction in cognitive function, and the risk of developing long-term vascular consequences are among the common symptoms of this condition. 2 There is now a considerable body of literature documenting the pathophysiology and consequences of OSA; however, the morbidity, benefits of treatment, and optimal mode of management of OSA remain a clinical dilemma.
CPAP has been proposed as the most effective treatment for OSA. Applying CPAP during the night is effec-tive in reducing symptoms of sleepiness and improving quality of life measurements in people with OSA. 3 However, CPAP is a constraining treatment with frequent local adverse effects that can constitute an obstacle to regular and prolonged use of the apparatus, 4 so individuals may abandon or adhere poorly to this therapy. Of OSA patients in whom CPAP is recommended, 5-50% reject this treatment and 12-25% of the remaining patients can be expected to discontinue CPAP, 5, 6 and the milder the symptoms of OSA, the less likely are the subjects to accept CPAP. Besides, although there is no doubt that CPAP is usually very effective, increased healthcare costs with this treatment may be another important factor that affects its adherence in patients with OSA. 7 Oral appliances (OAs) have emerged as an increasingly popular alternative for CPAP over the past decade. 8 The rationale behind the use of OAs is unclear, but is probably multifactorial, involving both a structural change with enhancement of the caliber of the airway and also triggering of stretch receptors, which activate the airway support muscles. 9 Several studies have demonstrated that OAs can effectively reduce the severity of sleep-disordered breathing and lead to symptomatic improvement, and patients seem to be more adherent to OAs than to CPAP. 10, 11 Many randomized trials have compared the outcomes of OAs versus CPAP in the treatment of patients with OSA, [10] [11] [12] [13] [14] [15] most of which indicate that OAs are less effective in reducing AHI but are preferred over CPAP. However, none of these trials has been large enough to confirm the outcomes within subgroups. Therefore, a meta-analysis that allows for the pooling and quantification of results from different studies is required to overcome this limitation. The present systematic review and meta-analysis was performed to compare the outcomes of OAs with those of CPAP.
Methods

Search Strategy
A computerized search of PubMed (1966 to May 2012), EMBASE (1984 to May 2012 , and the Cochrane Controlled Trials Register (2nd quarter, 2012) was carried out. The search strategy consisted of a combination of key words concerning the therapies (continuous positive airway pressure, CPAP, oral appliance, OA) and the disease (obstructive sleep apnea, OSA). These key words were used as MESH headings and free text words. All searches were limited to humans, clinical trial, review and metaanalysis. In addition, manual searching of reference lists from potentially relevant papers was performed, based on the computer-assisted strategy, to identify any additional studies that might have been missed.
Selection of Studies
Using a pre-defined protocol, 2 reviewers (LW and XL) independently selected studies for evaluation. Disagreements were resolved through consensus decision. The inclusion criteria were:
• Compared the outcomes of an OA versus CPAP in the treatment of patients with OSA
• Prospective and randomized
• Published in English and full-text available
• All data were included only once (replication was not permitted). Trials with nonclinical outcomes (eg, cephalometry) were excluded.
Data Extraction
Two reviewers independently performed the data extraction. For each trial, the following items were collected: first author, year of publication, design of the study, subject demography (number, mean age, and sex ratio), details of the inclusion criteria, types of OAs, types of CPAP devices, and study duration. The relevant outcomes pooled in this analysis included Epworth Sleepiness Scale (ESS), health-related quality of life, cognitive performance, blood pressure, apnea-hypopnea index (AHI), arousal index, minimum S pO 2 , percent rapid eye movement sleep, treatment usage (including nights/week and hours/night), side effects, subject preference, and withdrawals.
QUICK LOOK
Current knowledge
Both CPAP and oral appliances have been used for the treatment of obstructive sleep apnea. CPAP is more effective at reducing the apnea-hypopnea index, but oral appliances are better tolerated.
What this paper contributes to our knowledge
This meta-analysis of 14 comparative trials suggests that CPAP reduces apnea-hypopnea index and is more effective than oral appliances. There were no differences in treatment usage, treatment preference, side effects, or study withdrawals between CPAP and oral appliance.
Heterogeneity
A test for heterogeneity (Cochrane Q) was performed to identify inconsistency in the study results. However, because the test is susceptible to the number of trials included in the meta-analysis, we also calculated I 2 . This statistic, which is directly calculated from the Q statistic, describes the percentage of variation across the studies that is due to heterogeneity rather than change. I 2 ranges from 0% to 100%, with 0% indicating the absence of any heterogeneity. Although absolute numbers for I 2 are not available, values Ͻ 50% are considered low heterogeneity. When I 2 is Ͻ 50%, low heterogeneity is assumed, and the effect is thought to be due to change. Conversely, when I 2 exceeds 50%, then heterogeneity is thought to exist and the effect is random.
Assessment of Risk of Bias
Two independent investigators evaluated the risk of bias of the included studies according to the Collaboration's recommended tool (section 8.5 in chapter 8). 16 Briefly, the risk of bias of each study was assessed by using the following methodological components: randomization and generation of the allocation sequence; allocation concealment; subject blinding and examiner blinding; and description of the follow-up. The details of each methodological item are shown in Table 1 . However, the subjects knew which treatment they received, because the appearance of the OAs were obviously different from that of the CPAP devices, and it was impossible to make these treatment devices look alike, so blinding and allocation concealment could not be easily performed, and thus the trials with an adequate method of randomization and clear description of the follow-up were considered to be of low risk of bias. Besides, a particular concern with the crossover trials is the risk of a carry-over effect, which occurs when an intervention given in the first period has an effect that carries over into the second period and may influence subjects' responses in the subsequent period. Therefore, crossover trials with a wash-out period between treatments were generally regarded as having low risk of a carry-over effect. 17 
Statistical Analysis
We conducted the meta-analysis with statistics software (Revman 5.1, Cochrane Collaboration, Oxford, United Kingdom). Results are expressed as risk ratios and/or odds ratios with 95% CIs for dichotomous outcomes, and as mean differences with 95% CIs for continuous outcomes. For crossover trials the analyses for continuous outcome variables were conducted by using the generic inverse variance statistical method, where mean differences and standard errors were entered. A correlation coefficient of 0.5 was used throughout this meta-analysis to estimate the standard errors for some crossover trials, where the appropriate standard deviation of differences was not included in study reports. Sensitivity analyses were performed to assess the impact of the assumed correlation coefficient on the outcomes of meta-analyses by repeating the analyses assuming correlation coefficients of 0.3 and 0.7, respectively. A fixed effects model was initially used; however, we planned to use a random effects model if there was evidence of significant heterogeneity across trials (P Ͻ .10 Adequate: no blinding or incomplete blinding, but the review authors judge that the outcome was not likely to be influenced by lack of blinding; blinding of subjects and key study personnel ensured, and unlikely that the blinding could have been broken. Unclear: insufficient information to permit judgment of low risk or high risk. Not performed, if the trial was not double blind.
Examiner blinding
Adequate: no blinding of outcome assessment, but the review authors judge that the outcome measurement was not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken. Unclear: insufficient information to permit judgment of low risk or high risk. Not performed, if the trial was not double blind.
Withdrawals and Dropouts
Adequate: the number of and reasons for dropouts and withdrawals in all intervention groups were described, or it was specified that there were no dropouts or withdrawals. Unclear: insufficient reporting of attrition/exclusions to permit judgment of low risk or high risk (eg, number randomized not stated, no reasons provided for missing data). Inadequate: the number of and reasons for dropouts and withdrawals were not described.
and I 2 Ͼ 50%). A sensitivity analysis was performed to explore the potential source of heterogeneity. We also planned to use funnel plot asymmetry to assess for publication bias. Figure 1 shows the details of study identification, inclusion, and exclusion. The literature search yielded 1,216 articles. By screening the titles and abstracts, 1,123 papers were excluded due to the irrelevance to this topic. In 93 potentially relevant references, 17 papers were taken for a comprehensive evaluation. After retrieving the full articles, one was excluded because of duplicated data 18 and 2 were excluded because of nonclinical outcomes. 19, 20 Finally, 14 studies were included in this metaanalysis. [10] [11] [12] [13] [14] [15] [21] [22] [23] [24] [25] [26] [27] [28] Among these studies, 8 trials had a crossover design, [10] [11] [12] 15, [21] [22] [23] 27 and 6 had a parallel-group design. 13, 14, [24] [25] [26] 28 The main characteristics of the included studies are shown in Table 2 .
Results
Risk of Bias in These Trials
The assessment of risk of bias in all included studies is shown in Table 3 . A method of block randomization was used in 6 trials. 14, 22, [24] [25] [26] 28 Adequate method for allocation concealment was applied in 3 trials. 14, 27, 28 In one trial, 28 the subjects remained blinded to the nature of therapy, and examiner blinding was performed in 3 trials. 22, 27, 28 The description of follow-up was considered adequate in all included trials. So over half of the included trials, with 3 or more methodological components inadequate or unclear, were regarded as having a high risk of bias. A washout period between treatments was described in 6 of the 8 crossover trials, 10, 12, 15, 21, 23, 27 and those 6 were considered to have a low risk of carry-over effect.
Clinical Outcomes
Score of Epworth Sleepiness Scale. There were 5 crossover trials 12, 15, [21] [22] [23] and 3 parallel-group trials 13, 14, 24 reporting the score of ESS. The test for heterogeneity detected a significant heterogeneity across the crossover trials (P Ͻ .001, I
2 ϭ 88%), while there was no evidence of heterogeneity across the parallel-group trials (P ϭ .85, I 2 ϭ 0%). Pooled estimates revealed that there was no significant difference between treatments, both in crossover trials (mean difference 0.74, 95% CI -0.69 to 2.17, P ϭ .31) and in parallel-group trials (mean difference 1.33, 95% CI -0.19 to 2.85, P ϭ .09) (Fig. 2) .
Health-Related Quality of Life. Two crossover trials 12, 22 reported the data on the Functional Outcomes of Sleepiness Questionnaire, and pooled estimates showed no significant difference between groups (mean difference Ϫ0.43, 95% CI -1.41 to 0.54, P ϭ .38), but with a significant heterogeneity across the trials (P ϭ .008, I
2 ϭ 86%) (see Fig. 2 ). There were 2 crossover trials 12,22 and 3 parallelgroup trials 13, 14, 28 reporting the outcome of the 36-item Medical Outcomes Study Short Form questionnaire (SF-36). In the trial by Engleman et al, 22 CPAP-treated subjects had significantly higher SF-36 scores for the health transition and mental components (P ϭ .001 and .008, respectively), while there were no significant difference in the SF-36 physical component scores between treatments. Barnes et al 12 reported that there was no significant difference regarding SF-36 mean scores between the groups. Two parallel-group trials 13, 14 reported component scores from the SF-36, and pooled estimates revealed no significant difference regarding each component score between treatments. Aarab et al 28 reported that the changes in the domains of the SF-36 were not significantly different between groups. One crossover trial 22 and one parallel-group trial 14 reported the data on Hospital Anxiety and Depression Scale, both of which showed that the Hospital Anxiety and Depression Scale scores did not differ significantly between treatments.
Cognitive Performance. There were 3 crossover trials reporting the outcome of cognitive performance. In the trial by Engleman et al 22 it was shown that no significant differences in performance intelligence-quotient decrement score, Trail Making Test B, Steer Clear Performance Test, and Paced Auditory Serial Addition Test 2s correct was detected between treatments. Barnes et al 12 reported that there was no significant difference regarding the cognitive function assessed by Paced Auditory Serial Addition Blood Pressure. Two crossover trials and one parallelgroup trial reported the outcome of blood pressure. In the trial by Engleman et al 22 it was reported that, although there was no significant response in the 24-hour mean systolic or diastolic blood pressure between groups, OAtreated subjects had a significantly lower nighttime dia- 
Polysomnography Outcomes
Apnea Hypopnea Index. There were 6 crossover trials 10-12,21-23 and 3 parallel-group trials 13, 14, 28 reporting AHI. The test for heterogeneity revealed a significant heterogeneity across the crossover trials (P ϭ .008, I 2 ϭ 68%), while no evidence of heterogeneity was detected across the parallel-group trials (P ϭ .41, I
2 ϭ 0%). Overall, OAtreated subjects had significantly more apneas and hypopneas, both in the crossover trials (mean difference 8.25, 95% CI 5.89 -10.61, P Ͻ .001) (Fig. 3) and the parallelgroup trials (mean difference 5.96, 95% CI 3.40 to 8.51, P Ͻ .001) (see Fig. 3 ).
Arousal Index. Five crossover trials 10-12,21,23 and 2 parallel-group trials 13, 28 reported arousal index. Pooled estimates of the crossover trials found a significant difference in favor of CPAP (mean difference 3.10, 95% CI 1.23-4.96, P ϭ .001), but with a significant heterogeneity across the trials (P ϭ .06, I
2 ϭ 55%) (see Fig. 3 ). While the pooled estimates of the parallel-group trials revealed no significant difference between treatments (mean difference 3.18, 95% CI -1.17 to 7.52, P ϭ .15), the results were robust and there was no heterogeneity across the trials (P ϭ .32, I
2 ϭ 0%) (see Fig. 3 ).
Minimum S pO 2 . There were 4 crossover trials [10] [11] [12] 21 and 4 parallel-group trials 13, 14, 25, 26 reporting minimum S pO 2 . Pooled estimates of crossover trials showed that OA-treated subjects had a significantly lower minimum S pO 2 (mean difference Ϫ5.11%, 95% CI -6.91 to -3.30, P Ͻ .001), but there was substantial heterogeneity across the trials (P ϭ .003, I 2 ϭ 78%) (see Fig. 3 ). However, pooled estimates of the parallel-group trials found no significant difference between treatments (mean difference Ϫ0.94, 95% CI -2.50 to 0.62, P ϭ .24), with no evidence of heterogeneity across the trials (P ϭ .14, I
2 ϭ 45%) (see Fig. 3 ).
Rapid Eye Movement Sleep. Four crossover trials 10, 11, 21, 23 and 2 parallel-group trials 14, 28 reported the outcome of percent rapid eye movement sleep. The test for heterogeneity detected significant heterogeneity across the crossover trials (P Ͻ .001, I
2 ϭ 84%), and pooled estimates found no significant difference between treatments (mean difference Ϫ0.27, 95% CI -3.75 to 3.22, P ϭ .88) (see Fig. 3 ). While the pooled estimates of the parallelgroup trials showed a significant difference in favor of CPAP (mean difference 2.42, 95% CI 0.31 to 4.53, P ϭ .02), there was no heterogeneity across the trials (P ϭ .97, I 2 ϭ 0%) (see Fig. 3 ).
Other Related Outcomes
Treatment Usage. There were 2 crossover trials 12, 22 reporting treatment usage of hours/night, and 4 parallel-group trials 13, 14, 25, 26 reporting treatment usage of hours/night and nights/week. There was significant heterogeneity across the crossover trials (P Ͻ .001, I
2 ϭ 95%, hours/night) and across the parallel-group trials (P Ͻ .001 and I 2 ϭ 93% for hours/night, and P ϭ .09 and I 2 ϭ 54% for nights/week). The pooled estimates showed no significant difference between treatments both in the crossover trials (mean difference 1.01, 95% CI -0.75 to 2.78, and P ϭ .26 for hours/ night) (Fig. 4) and in the parallel-group trials (mean difference 0.82, 95% CI -0.27 to 1.91, and P ϭ .14 for hours/night, and mean difference 0.16, 95% CI -0.08 to 0.40, and P ϭ .19 for nights/week) (see Fig. 4 ).
Treatment Preference.
Five crossover trials reported the outcome of treatment preference. The trials by Ferguson et al 10, 21 reported that most subjects who were treated successfully preferred CPAP to OAs, but OA was preferred as a long-term treatment among these subjects. Engleman et al 22 reported that a 5-variable model explained 68% of the variance in treatment preference, and eventually identified 83% and 90% of subjects, respectively, preferring OA and CPAP. Barnes et al 12 reported that the overall percentages of preferred treatment were 30% for OA and 44% for CPAP. While Gagnadoux et al 15 reported that 71.2% of subjects preferred OA, 8.5% preferred CPAP, and 8 subjects had no treatment preference.
Side Effects. There were 6 crossover trials and 2 parallel-group trials reporting side effects. Ferguson et al 10, 21 found mild side effects common with OA, including sore teeth, sore jaw muscles, and excessive salivation, while CPAP-treated subjects more commonly had moderate to severe side effects, such as nasal congestion, rhinorrhea, eye irritation, and a sense of suffocation. Randerath et al 11 reported that CPAP-treated subjects often had a sense of pressure on the face, while OA-treated subjects often had early morning discomfort in the mouth. Engleman et al 22 reported that side effects were common both for OAs and CPAP; however, some side effects were treatment-specific, such as dental pain or salivation with OA, and stuffy nose or mask problems with CPAP. Gagnadoux et al 15 reported that the mean side effects scores were similar for OA and CPAP in the subjects who completed the study (P ϭ .80). Lam et al 13 and Aarab et al 28 both reported that 
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RESPIRATORY CARE • JULY 2013 VOL 58 NO 7nearly all subjects reported side effects, but that all side effects were considered mild and acceptable. 10 reported that one subject dropped out during the wash-in period and one dropped out in the OA treatment period. In another trial by Ferguson et al, 21 one subject withdrew in the OA treatment period and 3 refused to cross over to the CPAP treatment arm. Tan et al 23 and Gagnadoux et al 15 both reported that 2 subjects dropped out in the CPAP treatment period and one withdrew in the OA treatment period. Trzepizur et al 27 reported one dropout from the CPAP group. Five parallelgroup trials reported withdrawals, 13, 14, 25, 26, 28 and the pooled estimates showed no significant difference between treatments (odds ratio 1.56, 95% CI 0.62-3.94, P ϭ .34), with no evidence of heterogeneity (P ϭ .28, I
Withdrawals. Ferguson et al
2 ϭ 22%) (see Fig. 4 ).
Discussion
Although many randomized trials have supported the evidence that CPAP is more effective than OAs in reducing OSA, [10] [11] [12] [13] [14] [15] some studies have suggested that the efficacy of OAs in modifying the health risks associated with OSA is somewhat similar to that of CPAP. 29 A previous Cochrane review 8 showed that OAs were less effective than CPAP in reducing AHI and improving minimum S pO 2 during sleep; however, subjects seemed to be more adherent to OAs than CPAP in a small part of the included trials. So the prior Cochrane review led to the conclusion that CPAP seemed to be more effective than OAs in improving sleep-disordered breathing, but the difference in symptoms between these 2 treatments was not significant.
However, the results of the prior Cochrane review were not completely convincing. The main reason was that nearly all the included crossover trials in the prior Cochrane review did not report any paired results, though they did provide means and SDs for the outcomes of each treatment. In this case, paired analyses from these crossover trials could only be approximated by assuming a certain degree of correlation between the 2 treatment outcomes. The reviewers used a correlation coefficient of zero, which was equivalent to a parallel group analysis of the results. The limitation by doing this involved the fact that the particular strength of crossover design was ignored, where treatments were evaluated on the same subjects, allowing comparison at the individual rather than the group level. 30 Therefore, the validity of the pooled estimates of the crossover trials in the prior Cochrane review needed further confirmation.
In the present systematic review and meta-analysis, a correlation coefficient of 0.5 was used to estimate the standard errors for some included crossover trials, where the appropriate standard deviations of the differences were not included in the study reports. Our results demonstrated that OA-treated subjects had similar ESS scores, when compared to CPAP-treated subjects, both in crossover (P ϭ .31) and parallel-group (P ϭ .09) trials. In addition, the effects of OAs and CPAP on health-related quality of life, cognitive performance, and blood pressure were also similar, but CPAP may produce a better outcome than OA. From the above results, it can be concluded that OAs and CPAP yield fairly similar results in terms of these clinical outcomes.
As for the polysomnography (PSG) outcomes, the pooled estimates of the crossover trials suggested a significant difference in favor of CPAP with regard to AHI (P Ͻ .001), arousal index (P ϭ .001), and minimum S pO 2 (P Ͻ .001). The pooled estimates of parallel-group trials showed that, compared with CPAP-treated subjects, OA-treated subjects had significantly more apneas and hypopneas (P Ͻ .001). Moreover, a significant difference in favor of CPAP was detected regarding percent rapid eye movement sleep (P ϭ .02). The above results may lead to a conclusion that CPAP yielded better PSG outcomes than OAs, especially in reducing AHI. Treatment success with OA, defined as an AHI of Ͻ 5 events/hour, was found in 19 -75% of the subjects. An AHI of Ͻ 10 events/hour was reported in 30 -94% of the subjects. However, CPAP reduced AHI more efficiently and gave a higher success rate in all these studies. [10] [11] [12] [13] [14] [15] [21] [22] [23] Overall, these PSG outcomes (especially hypoxia) are of crucial importance with regard to survival and morbidity in subjects with OSA, which emphasizes the relevance of optimal suppression of respiratory disturbances and argues against OA's treatment effect on OSA in terms of these respiratory parameters, 31, 32 indicating that OAs can be given only for those who refuse CPAP.
As far as other related outcomes were concerned, the pooled estimates revealed no significant difference between OA and CPAP with regard to treatment usage (P ϭ .26 for hours/night in the crossover trials, and P ϭ .14 for hours/ night and P ϭ .19 for nights/week in the parallel-group trials) and withdrawals (P ϭ .34 in the parallel-group trials).
Side effects were common with both OAs and CPAP, with a similar severity across treatments. Moreover, although the subjects generally preferred OA to CPAP, similar preferences for OA and CPAP were reported. The above results lead us to draw the conclusion that OAtreated subjects have similar results regarding all these related outcomes, when compared with CPAP-treated subjects.
Although a substantial heterogeneity was detected in all pooled estimates of crossover trials, it could be eliminated by the sensitivity analysis. After excluding the major contributors to the heterogeneity, the pooled estimates still got the same results regarding all these outcomes ( Table 4 ), indicating that the heterogeneity did not have a significant effect on the pooled estimates of the crossover trials. In addition, a sensitivity analysis performed by repeating the analyses assuming correlations of 0.3 and 0.7 revealed that the assumed correlation of 0.5 did not affect the pooled estimates of the crossover trials with regard to all these outcomes (Table 5) . While the heterogeneity across the parallel-group trials was slight, most of the evidence from the analyses should be considered robust. But there was substantial heterogeneity in the analysis of treatment usage, the major contributor to heterogeneity was the study by Lam et al. 13 By removing this study the heterogeneity was eliminated (P ϭ .16 and I 2 ϭ 46% for hours/night, and P ϭ .47 and I 2 ϭ 0% for nights/week), and the pooled estimates indicated a significant difference in favor of OA in treatment usage of hours/night (P ϭ .04), but there was still no significant difference in treatment usage of nights/ week between treatments (P ϭ .29).
Nevertheless, the present systematic review and metaanalysis still had several potential limitations. One potential limitation was that the degree of mandibular advancement by the OAs and the OA designs were variable among the included trials, which caused uncertainty regarding comparisons between these studies. A second potential limitation involved the fact that most of the included trials had high risk of bias, due to 3 or more unclear or inadequate methodological components. Moreover, a few of the included crossover trials 11, 22 had a high risk of a carryover effect, due to the absence of a wash-out period between treatments.
A third limitation was the small sample sizes of all the included trials and the small number of studies. A funnel plot for pooled estimates to assess the potential publication bias was not performed, and unpublished studies with negative results could not be identified, so there might be publication bias as well, which could result in overestimation of the effectiveness of the interventions.
Conclusions
CPAP has yielded better PSG outcomes than OA, especially lower AHI, indicating that OAs are less effective than CPAP in improving sleep-disordered breathing. If sleep-disordered breathing is left inadequately controlled, the long-term risk of systemic morbidity associated with OSA may be substantial, which may also suggest that CPAP is more reliable than OA in treatment of OSA. However, similar results from OA and CPAP in terms of clinical and other related outcomes were found, including ESS score, health-related quality of life, and treatment usage. Based on this evidence it would appear proper to offer OA to patients who are unable or unwilling to persist with CPAP. 
